

1 A year of Covid-19 GWAS results from the GRASP portal reveals potential SARS-CoV-2 modifiers

2

3 Florian Thibord¹, Melissa V. Chan¹, Ming-Huei Chen¹, Andrew D. Johnson^{1,*}

4

5 ¹Division of Intramural Research, Population Sciences Branch, Framingham, MA 01702

6 *corresponding author: johnsonad2@nhlbi.nih.gov

7

8

9 Abstract

10 Host genetic variants influence the susceptibility and severity of several infectious
11 diseases, and the discovery of novel genetic associations with Covid-19 phenotypes could help
12 developing new therapeutic strategies to reduce its burden.

13 Between May 2020 and June 2021, we used Covid-19 data released periodically by UK
14 Biobank and performed 65 Genome-Wide Association Studies (GWAS) in up to 18 releases of
15 Covid-19 susceptibility (N=18,481 cases in June 2021), hospitalization (N=3,260), severe
16 outcomes (N=1,244) and death (N=1,104), stratified by sex and ancestry.

17 In coherence with previous studies, we observed 2 independent signals at the
18 chr3p21.31 locus (rs73062389-A, OR=1.21, $P=4.26 \times 10^{-15}$ and rs71325088-C, OR=1.62,
19 $P=2.25 \times 10^{-9}$) modulating susceptibility and severity, respectively, and a signal influencing
20 susceptibility at the *ABO* locus (rs9411378-A, OR=1.10, $P=3.30 \times 10^{-12}$), suggesting an increased
21 risk of infection in non-O blood groups carriers. Additional signals at the *APOE* (associated with
22 severity and death) *LRMDA* (susceptibility in non-European) and chr2q32.3 (susceptibility in

23 women) loci were also identified but did not replicate in independent datasets. We then
24 devised an original approach to extract variants exhibiting an increase in significance over time.
25 When applied to the susceptibility, hospitalization and severity analyses, this approach revealed
26 the known *DPP9*, *RPL24* and *MAPT* loci, amongst thousands of other signals. Finally, this
27 significance trajectory analysis was applied to the larger Covid-19hgi meta-analyses, where
28 additional loci of interest, related to the immune system, were identified.

29 These results, freely available on the GRASP portal, provide new insights on the genetic
30 mechanisms involved in Covid-19 phenotypes.

31

32 Introduction

33

34 The severe acute respiratory syndrome – coronavirus 2 (SARS-CoV-2) is responsible for
35 the coronavirus disease 2019 (Covid-19) which affects individuals with variable severity, ranging
36 from asymptomatic patients to mild respiratory symptoms, hypercytokinemia, pneumonia,
37 thrombosis and even death.^{1,2} Understanding the mechanisms leading to heterogeneous
38 symptoms and susceptibility is essential in order to develop efficient treatments and improve
39 patient care. Host genetic diversity has been shown to influence the effects of infection to
40 several viruses,³ such as variations in *CCR5* [MIM: 601373] leading to HIV resistance⁴ [MIM:
41 609423] or *IRF7* [MIM: 605047] deficiency affecting *Influenza* susceptibility [MIM: 614680].⁵

42 In order to discover human genetic determinants to Covid-19 susceptibility and severity,
43 several biobanks and research groups worldwide collaborated to perform Genome-Wide
44 Association Studies (GWAS) and meta-analyses of the GWAS. In June 2020, a study involving

45 1,980 Covid-19 infected patients with respiratory failure was the first to reveal genome-wide
46 significant ($P < 5 \times 10^{-8}$) associations at the 3p21.31 locus, encompassing *SLC6A20* [MIM:
47 605616] and several chemokine receptors, and at the *ABO* [MIM: 110300] locus on
48 chromosome 9.⁶ These 2 signals were later validated in independent analyses for both Covid-19
49 susceptibility and severity^{7,8} while additional significant associations were observed at loci
50 involved in immune response or inflammation, such as *IFNAR2* [MIM: 602376], *DPP9* [MIM:
51 608258], *TYK2* [MIM: 176941], *CCHCR1* [MIM: 605310] and *OAS1* [MIM: 164350]. Notably,
52 these findings implicate common and uncommon variants, while studies trying to identify
53 associations of rare variants have been unsuccessful so far.⁹ The largest effort is currently led by
54 the Covid-19 host genetics initiative (Covid-19hgi),¹⁰ which completed meta-analyses of results
55 shared by 61 studies as of June 15th 2021, and plan to release new results as additional data is
56 made available. A major contributor to this group is the UK Biobank (UKB)¹¹ which periodically
57 releases the results of Covid-19 tests and related deaths, as well as health care data for its
58 nearly 500,000 consented participants, to approved researchers.

59 We created a public Covid-19 GWAS results portal
60 (<https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx>) in order to provide rapid deep
61 annotation for emerging genetics results and facilitate open access to the scientific community.
62 We contribute to this resource by performing GWAS on each Covid-19 data release from the UK
63 Biobank, including sex-specific, ancestry-specific, and trans-ethnic Covid-19 related GWAS,
64 along with a deep set of annotations for top variants (with $P < 1 \times 10^{-5}$). For each release, up to
65 65 GWAS have been generated including Covid-19 susceptibility, Covid-19 hospitalization,
66 severe Covid-19 with respiratory failure, and Covid-19 death. Here we describe the results of

67 these GWAS, 612 in total as of June 18th 2021, and report the evolution of signals associated
68 with these Covid-19 phenotypes over the consecutive datasets released by UKB since May
69 2020. The latter approach, tracking the evolution of genetic signatures iteratively in UKB,
70 suggests a valuable new analytic approach in genetic biobank studies where emerging true
71 signals may be identified before they reach genome-wide significance based on their
72 trajectories of significance.

73

74

75 Materials and Methods

76

77 UKB data

78 Analyses are based on v.3 of the UKB imputed dataset,¹² which provide genomic data
79 for 487,320 participants from multiple ethnicities, including 459,250 of European ancestry
80 (EUR), 7,644 of African ancestry (AFR), 9,417 of South Asian ancestry (SAS) and 11,009 of other
81 ancestries (OTHERS). Participants were enrolled at ages ranging from 37 to 73 and are 51.16%
82 female. UKB started to release Covid-19 test results of its participants on March 15th 2020, and
83 periodically update this resource as new cases are reported. Furthermore, information about
84 Covid-19 related death was made available from June 2020, while inpatient data and primary
85 care data was first added during the summer of 2020 and are periodically updated. Details
86 regarding the definition and selection of cases with Covid-19 susceptibility, Covid-19
87 hospitalization, Covid-19 severity, and Covid-19 death are available in **Table S1**.

88 Depending on the Covid-19 phenotype analyzed (susceptibility, hospitalization, severity,
89 or death), up to 3 different subsets of participants were used as controls. For Covid-19
90 susceptibility, cases with positive test results were analyzed against either participants tested
91 with negative results (labelled Tested), or against all participants without a positive test
92 (labelled Population). For analyses of Covid-19 hospitalization, patients hospitalized due to
93 Covid-19 were tested against non-hospitalized participants with a positive test (Positive), or
94 non-hospitalized participants with a test (Tested), or against all non-hospitalized participants
95 (Population). For analyses of Covid-19 severity, patients requiring invasive respiratory support
96 or patients who died from complications were tested against non-severe participants with a
97 positive test (Positive), or non-severe participants with a test (Tested) or all non-severe
98 participants (Population). For analyses of Covid-19 death, patients with Covid-19 death were
99 tested against participants with a positive test (Positive), or participants with a test (Tested) or
100 against all participants (Population).

101

102 Analyses

103 Each GWAS was conducted with SAIGE v0.38,¹³ which controls for population
104 stratification, relatedness and case-control imbalance, and adjusted for baseline age (at
105 enrollment), sex and 10 genetic principal components. For the results uploaded to the GRASP
106 portal, variants were filtered on imputation quality ($r^2 > 0.3$), minor allele count (MAC > 2), and
107 minor allele frequency (MAF > 0.0001). However, for the results presented in this manuscript,
108 we applied a more stringent filter, and considered only well-imputed variants ($r^2 > 0.8$) and
109 common variants (MAF > 0.01). After applying this filter, the lambda (genomic control factor)

110 ranged from 0.988 to 1.027 in all 65 analyses of the last data release analyzed (Table S2),
111 indicating no systematic inflation. For analyses prior to the June 18th 2020 release, we
112 conducted analyses on participants of European ancestry only, and started adding new analyses
113 stratified by sex and ancestry from June 18th 2020 onward. GWAS were stratified for EUR, AFR,
114 SAS, and OTHERS ancestries, and an additional trans-ancestry GWAS combining all participants
115 (labelled ALL) as well as GWAS combining non-European (nEUR) participants were performed.

116 Associations are either reported as odd ratios (OR) and 95% confidence intervals or as
117 beta coefficients (β) and associated standard errors (SE). Linkage disequilibrium (LD) was
118 estimated by squared correlation (r^2) using UKB EUR imputed data. Given the large number of
119 variants that may be significantly (or suggestively) associated at a locus, we assigned
120 significantly (or suggestively) associated variants to a common locus if they were separated by
121 less than 1Mb, and only reported the lead variant at that locus. To test 2 observed effects are
122 equal, we used the Z statistic: $Z = \frac{b_1 - b_2}{\sqrt{SEb_1^2 + SEb_2^2}}$, with b_1 and b_2 corresponding to the observed
123 effects and SEb_1 and SEb_2 the associated standard errors. In addition, haplotype analyses were
124 performed with the LDlink LDhap tool,¹⁴ while regional association plots were generated with
125 locuszoom.¹⁵

126

127 Annotation

128 For each analysis hosted on the portal, we provide comprehensive annotation for top
129 results ($P < 1 \times 10^{-5}$) using ANNOVAR¹⁶ and the RESTful API service provided by CADD v1.6.¹⁷ We
130 also retrieve known phenotype associations extracted from the GRASP¹⁸ and EBI GWAS

131 catalogs,¹⁹ and known eQTLs extracted from GTeX v8²⁰ and other eQTL resources compiled
132 from nearly 150 datasets (built upon the work of Zhang *et al*,²¹ detailed in **Table S3**).

133

134 Significance Trajectory Analyses

135 All 65 analyses were updated as soon as new data was released from UKB. As a result,
136 we obtained results for these analyses at different time points, which differed by the addition
137 of new cases, thus increasing power in most recent analyses. With an increase in power, *bona*
138 *fide* signals associated with Covid-19 phenotypes should increase in significance in each
139 consecutive data release analyzed. We designed a workflow to extract these signals with
140 positive significance trajectory in each analysis: for each variant (i) in the most recent data
141 release analyzed, $P < 10^{-4}$; (ii) in the first data release analyzed, P must be greater than in the
142 most recent data release analyzed; (iii) P cannot decrease in significance by more than one
143 order of magnitude between 2 consecutive releases; (iv) P must have increased in significance
144 by more than 1 order of magnitude at least once between 2 consecutive releases; (v) the latest
145 P observed must have decreased by more than 1 order of magnitude since the minimal P
146 observed. This set of rules should ensure to extract variants which increased in significance
147 since we started performing these analyses, while allowing some stagnation, which might
148 happen due to random sampling and/or low case increase between 2 consecutive releases.

149

150 The Covid-19hgi datasets

151 For replication purposes and significance trajectory analyses, we used the publicly
152 available Covid-19hgi meta-analyses summary statistics (freeze 6) for Covid-19 susceptibility

153 (labelled C2, N = 112,612 cases), hospitalization (B2, N = 24,274) and severity (A2, N = 8,779
154 cases). These datasets are currently the largest analyses of Covid-19 phenotypes available.
155 Publicly available summary statistics do not include the 23andMe dataset, and a version of the
156 summary statistics without UKB was also made available for the B2 and C2 analyses. As there
157 was no overlap of samples with our analyses, we used these summary statistics to replicate our
158 novel findings from susceptibility and hospitalization analyses, as well as our suggestive findings
159 from the significance trajectory analyses. To replicate findings from our severe analyses, we
160 used the A2 summary statistics without UKB from the freeze 5 (the A2 results without UKB from
161 freeze 6 were not available). In addition, we retrieved Covid-19hgi summary statistics (with
162 UKB) from all publicly available freezes to perform significance trajectory analyses with the
163 Covid-19hgi datasets (freezes 2 to 6 for B2 and C2; freezes 3 to 6 for A2).

164

165 Data Availability

166 Permission was obtained to post UKB summary statistics under an approved application
167 (ID 28525). The association results are available on the portal, as well as annotated top results.
168 In addition to UKB summary statistics, results from other efforts are also hosted on the portal.
169 Authors of Covid-19 GWAS publications have been contacted to seek approval before hosting
170 the results of their analyses on the GRASP Covid-19 portal. Summary statistics at this time
171 include multiple releases of the Covid-19hgi group, severe hospitalization results from
172 Ellinghaus *et al*⁶ and the GenOMICC study,⁷ as well as hospitalization status and time to end
173 Covid-19 symptoms from the COLCORONA study,²² with all top results being re-annotated in
174 the common framework mentioned above.

175

176

177 Results

178

179 UKB Covid-19 demographics

180 Using the latest UKB data releases available at this point, with susceptibility and
181 hospitalization phenotypes analyzed on June 18th 2021, and severe Covid-19 and death
182 analyzed on May 9th 2021, we retrieved 86,435 participants with a Covid-19 diagnostic, of
183 which 18,481 tested positive. According to inpatient care data, 3,260 positive cases were
184 hospitalized, while 1,244 patients with severe Covid-19 diagnostic received respiratory support
185 and/or died from complications (**Table 1**). Since May 7th 2020, we analyzed up to 18 UKB data
186 releases regarding Covid-19 susceptibility, 8 data releases concerning Covid-19 related deaths,
187 6 for Covid-19 hospitalization and 5 for Covid-19 severity. Amongst Covid-19 positive
188 participants, we observed a global increase in the percentage of female cases, starting at 45.3%
189 at the first release analyzed, and reaching 52.8% in the last, while men were more likely to be
190 infected ($P = 8.06 \times 10^{-6}$), hospitalized ($P = 1.59 \times 10^{-45}$), or develop severe complications ($P =$
191 1.51×10^{-34}) and die from Covid-19 ($P = 2.12 \times 10^{-27}$) (**Table S4**). There was also a decrease in
192 the mean age of positive cases, ranging from 57.02 to 53.57, with a significant drop after the
193 2020 summer (**Table 2**), with younger individuals more likely to be infected ($P < 10^{-300}$) while
194 increase in age was associated with hospitalization ($P = 4.54 \times 10^{-90}$), severity ($P = 5.63 \times 10^{-108}$)
195 and death ($P = 1.11 < 10^{-122}$) (**Table S4**). Positive cases were mainly of European ancestry,
196 representing 85.5% of all Covid-19 positive participants in the first analysis and growing to

197 89.6% in the last. South Asian ancestry, African ancestry, and other ancestry represent 4.4%, 3%
198 and 3% of positive cases, respectively, in this UKB data release. However, compared to
199 European participants, non-European participants were enriched amongst cases ($P = 3.09 \times 10^{-33}$
200 for AFR, $P = 1.10 \times 10^{-91}$ for SAS, $P = 1.96 \times 10^{-6}$ for OTHERS), as well as hospitalized ($P = 2.05$
201 $\times 10^{-53}$ for AFR, $P = 1.89 \times 10^{-24}$ for SAS, $P = 6.69 \times 10^{-9}$ for OTHERS), severe cases ($P = 1.02 \times 10^{-17}$
202 for AFR, $P = 5.93 \times 10^{-11}$ for SAS, $P = 0.004$ for OTHERS) and deceased participants ($P = 2.17 \times$
203 10^{-14} for AFR, $P = 6.14 \times 10^{-9}$ for SAS, $P = 0.009$ for OTHERS) (**Table S4**).

204

205 Genome-wide significant results

206 Between May 2020 and June 2021, we observed several genome-wide significant ($P < 5$
207 $\times 10^{-8}$) signals across the 65 analyses. However, many signals were only punctually significant,
208 and only a handful of signals remained significant in subsequent data releases analyzed. For
209 instance, the analysis of Covid-19 susceptibility in participants of European ancestry, with
210 untested or negatively tested participants as controls (noted Population controls), revealed 8
211 signals reaching genome-wide significance at some point (**Figure 1**), of which only 2 remained
212 significant in the last data release analyzed (on 06.18.21) : the chr3p21.31 locus encompassing
213 *SLC6A20* and several chemokine receptors (rs73062389-A, MAF = 0.06, OR = 1.22 [1.16; 1.28], P
214 = 7.60×10^{-16}), and the *ABO* locus on chromosome 9 (rs9411378-A, MAF = 0.22, OR = 1.10 [1.07;
215 1.14], $P = 8.78 \times 10^{-12}$). These two loci were previously reported to modulate Covid-19
216 susceptibility in several studies.^{6-8,10}

217 Across all 65 analyses, 5 loci reached genome-wide significance in the last data releases
218 analyzed (on 06.18.21 for susceptibility and hospitalization, and 05.09.21 for severity and

219 death): the chr3p21.31 locus, *ABO*, *APOE* [MIM: 107741], *LRMDA* [MIM: 614537] and an
220 intergenic signal at the chr2q32.3 locus (**Table 3**). All associations with $P < 10^{-5}$, from all 65
221 analyses, are available in **Table S5**. In addition, all signals reaching genome-wide significance in
222 any data release analyzed are presented in **Figures S1-S46**. The signals reported in the following
223 correspond to results using Population controls, but after systematically applying the Z-test for
224 the equality of regression coefficients we did not observe a significant difference of effect when
225 using a different set of control, such as Tested controls ($P > 0.05$, **Figure S47**).

226
227 **The 3p21.31 locus.** This locus was associated with Covid-19 susceptibility, hospitalization and
228 severity, in EUR and ALL ancestries, regardless of the set of controls employed. However, as
229 mentioned in previous works,^{8,10} the lead variant associated with susceptibility was not in LD
230 with the lead variants for hospitalization nor severity ($r^2 < 0.01$) suggesting 2 distinct signals
231 modulating Covid-19 susceptibility and severity (**Figure S48**).

232
233 **ABO.** The *ABO* locus was associated with Covid-19 susceptibility for ALL and EUR participants,
234 using either Population or Tested controls. Using haplotype analyses with blood group tagging
235 variants, we determined the blood groups tagged by the lead variant associated with
236 susceptibility (rs9411378). For the 5 main blood groups, we used the following tagging
237 variants²³: rs41302905 (tagging for O2), rs8176743 (tagging for B), rs1053878 (tagging for A2),
238 rs8176719 (tagging for O1) and rs2519093 (tagging for A1). As a result, we observed that the
239 Covid-19 susceptibility variant was fully tagging A1 and A2 haplotypes, and partially tagging B

240 haplotypes (20% of B haplotypes) (**Figure S49**), suggesting an increased risk of infection for A1
241 and A2 carriers.

242

243 **APOE.** The *APOE* variant tagging for the APOE- ϵ 4 haplotype was initially significantly associated
244 with Covid-19 susceptibility in EUR (rs429358-C, MAF = 0.15, OR = 1.38 [1.24; 1.53], $P = 1.80 \times$
245 10^{-9} , on 07.14.20). This signal was notably the first report of a genetic determinant for Covid-19
246 susceptibility.²⁴ This previous report was based on UKB data but this signal was not replicated in
247 an independent dataset, and this association was greatly attenuated after the summer, when
248 the number of Covid-19 cases started to rise significantly and the mean age of infected
249 participants decreased (**Figure 1**). The interaction between the age of participants and the
250 *APOE* variant was significant ($P = 1.78 \times 10^{-9}$), which was further confirmed using a 2df test²⁵
251 with age and genotype ($P = 2.65 \times 10^{-9}$), suggesting that a subset of older participant carriers of
252 this variant was more at risk of Covid-19 infection. Remarkably, this signal became genome-
253 wide significant in the 05.09.21 data release analyses of death in ALL and EUR, and in the
254 analysis of Severe Covid-19 in EUR, which may suggest a mechanism leading to severe and
255 lethal complications after infection. However, there is no evidence of association in the larger
256 Covid-19hgi meta-analysis of Covid-19 severity (A2, freeze 5 without UKB, $P = 0.27$).

257

258 **Results from ancestry- and sex-stratified analyses.** In other ancestry-stratified GWAS (AFR, SAS
259 and OTHERS), no signal was found genome-wide significant in the last data release analyzed. In
260 the GWAS combining all non-European participants (nEUR), with Population controls, one signal
261 was found significant at the *LRMDA* locus on chromosome 10 (rs114026383-C, MAF = 0.02, OR

262 = 2.39 [1.79; 3.20], $P = 4.10 \times 10^{-9}$). According to gnomAD (v2.1.1),²⁶ this variant is mostly
263 carried by individuals of African ancestry (MAF = 0.04) and mainly absent in other ancestries. In
264 the GWAS of African ancestry participants, this signal is close to genome wide significance ($P =$
265 1.55×10^{-7}). Interestingly, *LRMDA* variants have been found associated to lung function²⁷ [MIM:
266 608852] and HIV viral load in an unadjusted GWAS,²⁸ but there was no evidence of LD between
267 these variants and rs114026383 ($r^2 < 0.01$). Furthermore, this association did not replicate in
268 the Covid-19hgi susceptibility analysis (C2) restricted to African ancestry participants ($P=0.27$).

269 In addition, the chr3p21.31 susceptibility variant (rs73062389) was less frequent in non
270 Europeans, and we did not observe an association with this variant in any of the non European
271 ancestry-stratified analyses (MAF = 0.007 and $P = 0.22$ in AFR; MAF = 0.021 and $P = 0.47$ in SAS;
272 MAF = 0.038 and $P = 0.79$ in OTHERS). Similarly, there was no association at the *ABO* lead
273 variant (rs9411378) in non European ancestry-stratified analyses ($P = 0.18$ in AFR; $P = 0.22$ in
274 SAS; $P = 0.34$ in OTHERS).

275 In sex-stratified analyses, using Population controls, the chr3p21.31 susceptibility signal
276 was significant in women (rs73062389, $P = 1.06 \times 10^{-8}$ in ALL) and moderately associated in men
277 ($P = 2.10 \times 10^{-6}$ in ALL), whereas the *ABO* signal was significant in men (rs9411378, $P = 5.10 \times$
278 10^{-10} in ALL) and moderately associated in women ($P = 3.30 \times 10^{-5}$ in ALL). The chr3p21.31 lead
279 variant in the hospitalization analysis (rs72893671) was more significant in men ($P = 6.80 \times 10^{-11}$
280 in ALL) than in women ($P = 3.68 \times 10^{-4}$ in ALL). Despite these differences in significance between
281 men and women for these 3 main signals, we did not observe a significant difference of effect
282 when using the Z-test for the equality of regression coefficients ($P > 0.05$ for all 3 signals).
283 Additionally, a variant reached genome-wide significance in the analysis of Covid-19

284 susceptibility of women of ALL ancestry at the chr2q32.3 locus, while no association was
285 observed for this variant in men ($P = 0.47$). However this association was not supported by the
286 Covid-19hgi C2 analysis ($P = 0.58$), even though the Covid-19hgi meta-analyses were not sex-
287 stratified.

288

289 Signals with a positive significance trajectory in UKB

290 The significance trajectory of the most robust signals, at the chr3p21.31 and *ABO* loci,
291 mostly increased after the surge of new cases following the 09.08.20 data release (**Figure 1**).
292 After this date, the chr3p21.31 signal increased at each new data release and reached genome-
293 wide significance in the 11.03.20 release, while the *ABO* signal also increased and reached
294 significance in the 01.04.21 release. In order to identify signals that may become significant in
295 future releases, we extracted variants displaying a similar positive trajectory in significance over
296 time, and reaching at least $P < 10^{-4}$ in the last data release analyzed.

297 After applying our filters to each of the 65 analyses, the number of variants with a
298 positive significance trajectory summed up to 61,430. For each analysis, we extracted the lead
299 variant at each locus, which resulted into 11,821 lead variants (**Table S6**), with some duplicates,
300 as lead variants from a same locus can appear in several analyses (*i.e.* the chr3p21.31 locus,
301 which appears in 49 out of the 65 analyses). Notably, some of these loci previously reached
302 genome-wide significance in the Covid-19hgi meta-analyses¹⁰: the *DPP9* locus [MIM: 608258]
303 associated with hospitalization, the *NXPE3 / RPL24* locus [MIM: 604180] associated with
304 susceptibility, and the *MAPT* locus [MIM: 157140] associated with severe Covid-19.

305 In order to identify which variants with a positive trajectory reached at least nominal
306 significance in the Covid-19hgi analyses, we further focused on loci with positive significance
307 trajectory from the susceptibility, hospitalization and severe analyses, using ALL ancestry and
308 Population controls, which have the closest phenotype definition to the susceptibility (C2),
309 hospitalization (B2) and severity (A2) meta-analyses from Covid-19hgi, respectively. Signals with
310 a positive trajectory from Covid-19 susceptibility and hospitalization GWAS were sought for
311 replication in the corresponding C2 and B2 meta-analyses from Freeze 6 without UKB, while
312 signals from the severe Covid-19 GWAS were sought for replication in the A2 meta-analysis
313 from Freeze 5 without UKB. We identified 205 loci with a positive trajectory in the susceptibility
314 analysis, 193 with hospitalization, and 168 with severity. Out of these 566 signals, 430 were
315 present in the corresponding Covid-19hgi meta-analyses, of which 30 (7%) had a concordant
316 effect direction and $P < 0.05$ (**Table S7**). Notably, we observed a stringent gap in P-values from
317 the Covid-19hgi meta-analyses results between the top 7 signals, previously identified and
318 reaching $P < 10^{-16}$ (chr3p21.31, *ABO*, *DPP9*, and *RPL24*), and the remaining 23 signals which did
319 not reach $P < 10^{-3}$ (**Table 4**). Furthermore, amongst the variants missing in the Covid-19hgi
320 meta-analyses figured the lead variant at the *MAPT* locus (rs532052263), which had a positive
321 trajectory in the UKB severe analysis. However, we observed significant LD between this variant
322 and the known signal associated with severe Covid-19¹⁰ at this locus (rs8080583, $r^2 = 0.75$),
323 suggesting they both belong to the same signal.

324

325 Signals with a positive significance trajectory in Covid-19hgi meta-analyses

326

327 Finally, given the larger sample size and statistical power of the Covid-19hgi studies, we
328 applied the significance trajectory analyses to these datasets, where this approach might be
329 more effective to identify signals of interest. For the B2 and C2 analyses, we analyzed freezes 2
330 to 6, and we analyzed freezes 3 to 6 for the A2 analysis (all including the UKB dataset, but not
331 the 23andMe dataset). For this significance trajectory analysis, the same set of rules used for
332 the UKB analyses was applied, except that we only extracted variants reaching $P < 10^{-5}$ in the
333 last freeze (instead of $P < 10^{-4}$ in UKB), since these meta-analyses are better powered than the
334 UKB analyses. Over all 3 analyses, we identified a total of 9,697 variants with a positive
335 trajectory (**Table S8**). After clusterizing these variants into loci and extracting lead variants at
336 each locus, we obtained 51 lead variants for the A2 analysis, 89 for B2 and 85 for C2 (**Table S9**).

337 Out of these 225 loci, 34 reached genome-wide significance, and only 3 known genome
338 wide significant signals were not detected by the significance trajectory analysis: at the *CCHCR1*
339 locus [MIM: 605310] (in both B2 and A2 analyses) and at the *MUC5B* locus [MIM: 600770] (in
340 the B2 analysis), as both these loci decreased in significance by more than one order of
341 magnitude at some point. Furthermore, 2 loci that reached genome-wide significance only
342 when the 23andMe datasets were included in the Covid-19hgi meta-analyses were also
343 detected by our approach: at the *SFTPD* locus [MIM: 178635] and at the *SLC22A31* locus (both
344 in the B2 analysis). Additionally, we detected signals at the *ACE2* [MIM: 300335] and *TMPRSS2*
345 loci [MIM: 602060], 2 proteins involved in SARS-CoV-2 infection. A rare *ACE2* variant was
346 previously observed as significantly associated in the C2 Covid-19hgi meta-analysis
347 (rs190509934, MAF = 0.003, $P = 3.30 \times 10^{-17}$), but the significance trajectory analysis also
348 revealed a common variant (rs4646120, MAF = 0.49, $P = 2.30 \times 10^{-6}$) associated with Covid-19

349 susceptibility. At the *TMPRSS2* locus, a common exonic variant was detected in the A2 analysis
350 (rs12329760, MAF = 0.27, $P = 8.18 \times 10^{-6}$), and other intronic variants in LD with the exonic
351 variant were detected in the B2 analysis (rs915823, $P = 1.67 \times 10^{-6}$, LD $r^2 = 0.83$). Finally, several
352 signals detected in this approach might be of interest as they are located in, or near, genes
353 playing a role in immune response. For instance, intronic variants in the mucin genes *MUC4*
354 [MIM: 158372] (rs2260685, MAF = 0.46, $P = 1.76 \times 10^{-6}$) and *MUC16* [MIM: 606154]
355 (rs73005873, MAF = 0.36, $P = 7.81 \times 10^{-8}$) were identified in the C2 analysis, and 2 intergenic
356 variants close to interferon regulatory factors *IRF1* [MIM: 147575] (rs4143335, MAF = 0.14, $P =$
357 5.96×10^{-6}) and *IRF2* [MIM: 147576] (rs6854508, MAF = 0.17, $P = 9.26 \times 10^{-6}$) were identified in
358 the B2 analysis.

359

360 Discussion

361

362 This project was initiated with the major aim to share results of Covid-19 host genetics
363 analyses freely and rapidly on the GRASP portal, during a pandemic where new insights to
364 improve patient care and develop better treatments were greatly needed. A few months after
365 the first Covid-19 case was identified in the UK, we started to perform GWAS on each dataset
366 released by UKB between May 2020 and June 2021, and thus far examined genetic signals
367 associated with Covid-19 phenotypes across 18 data releases. This unique context allowed us to
368 track the evolution of genetic associations over time, an approach rarely applied. While some
369 works have examined the statistical properties of phased and nested case-control studies,^{29,30}

370 few studies have proposed using statistical significance trajectories over time in genetic
371 analyses.

372 As a first observation, the majority of signals observed in the first stages of the project
373 did not sustain over time. For instance, the first genome-wide significant association observed
374 in the GWAS of Covid-19 susceptibility in Europeans with rs34338189 as lead variant is not even
375 nominally significant in the last release ($P = 0.25$). Another genome-wide significant signal was
376 observed at the *APOE* locus, with a significance that increased in the first 4 data releases before
377 decreasing continually in the subsequent releases. The lead variant at the *APOE* locus is coding
378 in part for the *APOE*- $\epsilon 4$ haplotype, known to increase the risk of Alzheimer's disease [MIM:
379 607822], dementia, dyslipidemia and cardiovascular diseases [MIM: 617347] and is speculated
380 to cause inflammation and cytokine storms.³¹ Notably, the significant association of the *APOE*
381 signal with severe Covid-19 and death in most recent analyses could support this proposition,
382 but this association has not been replicated in an independent dataset. The evolution of the
383 *APOE* signal over time could also be due to an initial higher prevalence of Covid-19 in nursing
384 homes,³² where dementia patients were at higher risk of being infected and spreading the virus
385 due to living arrangements, and a poor understanding of transmission dynamics and
386 appropriate safety guidelines early in the pandemic. Overall, the evolution of these signals
387 suggests a change in the composition of cases over time, such as the diminution of age and
388 increase of positively tested women in the later data releases, as well as the introduction of
389 variant SARS-CoV2 strains. This change was most significant after the 2020 summer when a
390 surge in new Covid-19 infections occurred.

391 The most robust findings from our study are the association of the chr3p21.31 and *ABO*
392 loci with Covid-19 susceptibility and a distinct signal at the chr3p21.31 locus associated with
393 Hospitalization and severe Covid-19. These observations corroborate several previous reports,^{6–}
394 ^{8,10}. In order to detect additional suggestive signals, that may reach genome-wide significance in
395 future analyses, we developed an original strategy to identify associations displaying increased
396 significance over time, and identified thousands of variants with a positive significance
397 trajectory. Amongst these, 3 signals at the *DPP9*, *NXPE3*, and *MAPT* loci were previously
398 established variants associated with Covid-19 phenotypes, notably by the Covid-19hgi
399 analyses,¹⁰ thus demonstrating the potential of this approach. However, determining which
400 variants actually modulate Covid-19 phenotypes amongst thousands of candidates, without an
401 independent and well-powered dataset such as Covid-19hgi to confirm the validity of a signal, is
402 still challenging. Still, this approach might be valuable to reduce the scope of search. To further
403 reduce the scope of candidates, we applied this significance trajectory analysis to the larger
404 meta-analyses provided by the Covid-19hgi. Given the higher statistical power of these
405 analyses, we also applied a more stringent threshold, which allowed us to extract only variants
406 reaching $P < 10^{-5}$ in the last freeze. As a result, a lower and thus more workable number of loci
407 were extracted, among which several have a role in immune function, such as mucins,
408 interferon regulators, interleukin receptors, or HLA system related genes, which might be of
409 interest for the study of genetic mechanisms involved in Covid-19 phenotypes. However, these
410 associations are still only suggestive, and will need to be further validated either in future
411 releases or in independent datasets.

412 The associations we observed changing through the pandemic could reflect random
413 effects or changes in statistical power, but some of the results suggest changes due to potential
414 gene-environment interactions such as age, underlying health conditions (*APOE*) or sex makeup
415 of cases exposed to or engaging in risk behavior. This indicates the general approach of iterative
416 analysis and significance trajectory analyses for genetics during pandemics may have benefits in
417 uncovering pathophysiologic clues. Additionally, other factors like predominant virus strains
418 and changing treatment strategies through a pandemic might interact with host genetics, and
419 be better understood by iterative analyses. To enable such approaches in pandemics and other
420 critical research domains, rapid and extensive results sharing are important catalysts, as
421 demonstrated by the UKBB, COLCORONA, GenOMICC and Covid-19hgi.

422 In summary, our host genomic analyses of Covid-19 may contribute to improve the
423 comprehension of mechanisms involved in the infection and complications due to Covid-19.
424 Our study also has some limitations. Most importantly, our data and the work of others support
425 large health disparities between EUR and non-EUR individuals related to COVID-19 throughout
426 the ongoing pandemic. Despite an over-representation proportionally among cases and those
427 with severe and fatal outcomes, the non-EUR component of UKB and Covid-19hgi is a
428 proportionally small sample limiting our statistical power to address population-specific genetic
429 variants contributing to health outcomes. However, moving forward we feel that having a
430 diverse set of results with different phenotype definitions, sex-specific, ancestry-specific, and
431 including external group summary statistics, all in a common genome reference and annotation
432 framework may maximize the chance for new studies to cross-replicate or meta-analyze results
433 as Covid-19 genetic studies continue to grow.

434

435 Description of Supplemental Data

436 Supplemental Data include 50 figures and 9 tables.

437

438 Declaration of Interests

439 The authors declare no competing interests.

440

441 Acknowledgments

442 All authors were supported by NIH Intramural Research Program funds. The views expressed in

443 this manuscript are those of the authors and do not necessarily represent the views of the

444 National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S.

445 Department of Health and Human Services. This research has been conducted using the UK

446 Biobank Resource under Application Number 28525. UK Biobank was established by the

447 Wellcome Trust, Medical Research Council, Department of Health, Scottish government, and

448 Northwest Regional Development Agency. It has also had funding from the Welsh assembly

449 government and the British Heart Foundation. All UKB analyses for this manuscript were

450 conducted on the NIH Biowulf high performance computing cluster (<https://hpc.nih.gov/>). The

451 Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office

452 of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and

453 NINDS. We also thank the NHLBI IT team for their help in keeping the GRASP portal up to date,

454 David-Alexandre Tregouet for his helpful comments regarding the ABO haplotype analyses, and

455 the Covid-19 Host Genetics Initiative for sharing the results of their analyses.

456

457 Web Resources

458 GRASP Covid-19 resource: <https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx>

459 GTeX : <https://gtexportal.org/home/>

460 CADD : <https://cadd.gs.washington.edu/>

461 EBI GWAS catalog : <https://www.ebi.ac.uk/gwas/>

462 GRASP catalog : <https://grasp.nhlbi.nih.gov/Overview.aspx>

463 Covid-19hgi meta-analyses results : <https://www.covid19hg.org/results/r5/>

464 GnomAD : <https://gnomad.broadinstitute.org/>

465 LocusZoom : <https://locuszoom.org/>

466 LDlink : <https://ldlink.nci.nih.gov>

467

468

469 Data and Code Availability

470 The datasets generated during this study are available at the GRASP Covid-19 portal:

471 <https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx>

472

473 References

474 1. Connors, J.M., and Levy, J.H. (2020). COVID-19 and its implications for thrombosis and
475 anticoagulation. *Blood* 135, 2033–2040.

476 2. Tang, D., Comish, P., and Kang, R. (2020). The hallmarks of COVID-19 disease. *PLoS Pathog.*
477 16, e1008536.

478 3. Kwok, A.J., Mentzer, A., and Knight, J.C. (2021). Host genetics and infectious disease: new
479 tools, insights and translational opportunities. *Nat. Rev. Genet.* 22, 137–153.

- 480 4. Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y., Nagashima, K.A., Cayanan, C.,
481 Maddon, P.J., Koup, R.A., Moore, J.P., et al. (1996). HIV-1 entry into CD4+ cells is mediated by
482 the chemokine receptor CC-CKR-5. *Nature* 381, 667–673.
- 483 5. Ciancanelli, M.J., Huang, S.X.L., Luthra, P., Garner, H., Itan, Y., Volpi, S., Lafaille, F.G., Trouillet,
484 C., Schmolke, M., Albrecht, R.A., et al. (2015). Life-threatening influenza and impaired
485 interferon amplification in human IRF7 deficiency. *Science* 348, 448–453.
- 486 6. Ellinghaus, D., Degenhardt, F., Bujanda, L., Buti, M., Albillos, A., Invernizzi, P., Fernández, J.,
487 Prati, D., Baselli, G., Asselta, R., et al. (2020). Genomewide Association Study of Severe Covid-19
488 with Respiratory Failure. *N. Engl. J. Med.* 0, null.
- 489 7. Pairo-Castineira, E., Clohisey, S., Klaric, L., Bretherick, A.D., Rawlik, K., Pasko, D., Walker, S.,
490 Parkinson, N., Fourman, M.H., Russell, C.D., et al. (2020). Genetic mechanisms of critical illness
491 in Covid-19. *Nature* 1–1.
- 492 8. Shelton, J.F., Shastri, A.J., Ye, C., Weldon, C.H., Filshtein-Sonmez, T., Coker, D., Symons, A.,
493 Esparza-Gordillo, J., Aslibekyan, S., and Auton, A. (2021). Trans-ancestry analysis reveals genetic
494 and nongenetic associations with COVID-19 susceptibility and severity. *Nat. Genet.* 1–8.
- 495 9. Kosmicki, J.A., Horowitz, J.E., Banerjee, N., Lanche, R., Marcketta, A., Maxwell, E., Bai, X., Sun,
496 D., Backman, J.D., Sharma, D., et al. (2021). Pan-ancestry exome-wide association analyses of
497 COVID-19 outcomes in 586,157 individuals. *Am. J. Hum. Genet.* 0,
- 498 10. COVID-19 Host Genetics Initiative (2021). Mapping the human genetic architecture of
499 COVID-19. *Nature*.
- 500 11. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P.,
501 Green, J., Landray, M., et al. (2015). UK Biobank: An Open Access Resource for Identifying the
502 Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med.* 12, e1001779.
- 503 12. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic,
504 D., Delaneau, O., O’Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping
505 and genomic data. *Nature* 562, 203–209.
- 506 13. Zhou, W., Nielsen, J.B., Fritsche, L.G., Dey, R., Gabrielsen, M.E., Wolford, B.N., LeFaive, J.,
507 VandeHaar, P., Gagliano, S.A., Gifford, A., et al. (2018). Efficiently controlling for case-control
508 imbalance and sample relatedness in large-scale genetic association studies. *Nat. Genet.* 50,
509 1335–1341.
- 510 14. Machiela, M.J., and Chanock, S.J. (2015). LDlink: a web-based application for exploring
511 population-specific haplotype structure and linking correlated alleles of possible functional
512 variants. *Bioinforma. Oxf. Engl.* 31, 3555–3557.

- 513 15. Boughton, A.P., Welch, R.P., Flickinger, M., VandeHaar, P., Taliun, D., Abecasis, G.R., and
514 Boehnke, M. (2021). LocusZoom.js: Interactive and embeddable visualization of genetic
515 association study results. *Bioinforma. Oxf. Engl.* btab186.
- 516 16. Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic
517 variants from high-throughput sequencing data. *Nucleic Acids Res.* 38, e164–e164.
- 518 17. Rentzsch, P., Witten, D., Cooper, G.M., Shendure, J., and Kircher, M. (2019). CADD:
519 predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.*
520 47, D886–D894.
- 521 18. Eicher, J.D., Landowski, C., Stackhouse, B., Sloan, A., Chen, W., Jensen, N., Lien, J.-P., Leslie,
522 R., and Johnson, A.D. (2015). GRASP v2.0: an update on the Genome-Wide Repository of
523 Associations between SNPs and phenotypes. *Nucleic Acids Res.* 43, D799-804.
- 524 19. Buniello, A., MacArthur, J.A.L., Cerezo, M., Harris, L.W., Hayhurst, J., Malangone, C.,
525 McMahon, A., Morales, J., Mountjoy, E., Sollis, E., et al. (2019). The NHGRI-EBI GWAS Catalog of
526 published genome-wide association studies, targeted arrays and summary statistics 2019.
527 *Nucleic Acids Res.* 47, D1005–D1012.
- 528 20. Aguet, F., Brown, A.A., Castel, S.E., Davis, J.R., He, Y., Jo, B., Mohammadi, P., Park, Y.,
529 Parsana, P., Segrè, A.V., et al. (2017). Genetic effects on gene expression across human tissues.
530 *Nature* 550, 204–213.
- 531 21. Zhang, X., Gierman, H.J., Levy, D., Plump, A., Dobrin, R., Goring, H.H.H., Curran, J.E.,
532 Johnson, M.P., Blangero, J., Kim, S.K., et al. (2014). Synthesis of 53 tissue and cell line
533 expression QTL datasets reveals master eQTLs. *BMC Genomics* 15, 532.
- 534 22. Dubé, M.-P., Lemaçon, A., Barhdadi, A., Lemieux Perreault, L.-P., Oussaïd, E., Asselin, G.,
535 Provost, S., Sun, M., Sandoval, J., Legault, M.-A., et al. (2021). Genetics of symptom remission in
536 outpatients with COVID-19. *Sci. Rep.* 11, 10847.
- 537 23. Goumidi, L., Thibord, F., Wiggins, K.L., Li-Gao, R., Brown, M.R., van Hylckama Vlieg, A.,
538 Souto, J.-C., Soria, J.-M., Ibrahim-Kosta, M., Saut, N., et al. (2021). Association between ABO
539 haplotypes and the risk of venous thrombosis: impact on disease risk estimation. *Blood* 137,
540 2394–2402.
- 541 24. Kuo, C.-L., Pilling, L.C., Atkins, J.L., Masoli, J.A.H., Delgado, J., Kuchel, G.A., and Melzer, D.
542 (2020). ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank. *J. Gerontol. A. Biol.*
543 *Sci. Med. Sci.* 75, 1801–1803.
- 544 25. Kraft, P., Yen, Y.-C., Stram, D.O., Morrison, J., and Gauderman, W.J. (2007). Exploiting gene-
545 environment interaction to detect genetic associations. *Hum. Hered.* 63, 111–119.

- 546 26. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins, R.L.,
547 Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint spectrum
548 quantified from variation in 141,456 humans. *Nature* 581, 434–443.
- 549 27. Soler Artigas, M., Loth, D.W., Wain, L.V., Gharib, S.A., Obeidat, M., Tang, W., Zhai, G., Zhao,
550 J.H., Smith, A.V., Huffman, J.E., et al. (2011). Genome-wide association and large-scale follow up
551 identifies 16 new loci influencing lung function. *Nat. Genet.* 43, 1082–1090.
- 552 28. Ekenberg, C., Tang, M.-H., Zucco, A.G., Murray, D.D., MacPherson, C.R., Hu, X., Sherman,
553 B.T., Losso, M.H., Wood, R., Paredes, R., et al. (2019). Association Between Single-Nucleotide
554 Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in
555 Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of
556 AntiRetroviral Treatment Trial. *J. Infect. Dis.* 220, 1325–1334.
- 557 29. Van der Tweel, I., and van Noord, P.A. (2000). Sequential analysis of matched dichotomous
558 data from prospective case-control studies. *Stat. Med.* 19, 3449–3464.
- 559 30. Boessen, R., van der Baan, F., Groenwold, R., Egberts, A., Klungel, O., Grobbee, D., Knol, M.,
560 and Roes, K. (2013). Optimizing trial design in pharmacogenetics research: comparing a fixed
561 parallel group, group sequential, and adaptive selection design on sample size requirements.
562 *Pharm. Stat.* 12, 366–374.
- 563 31. Numbers, K., and Brodaty, H. (2021). The effects of the COVID-19 pandemic on people with
564 dementia. *Nat. Rev. Neurol.* 17, 69–70.
- 565 32. Chen, M.K., Chevalier, J.A., and Long, E.F. (2021). Nursing home staff networks and COVID-
566 19. *Proc. Natl. Acad. Sci. U. S. A.* 118, .

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589 Figure Titles and Legends

590

591 **Figure 1.** Evolution of significant signals associated with covid-19 susceptibility in UKB

592 participants of European ancestry, using Population as controls.

593 The top panel represents the evolution in significance of signals reaching genome wide significance at least

594 once across all data releases analyzed in Europeans for Covid-19 susceptibility. The middle panel represent

595 the mean age of cases in each data release. The bottom panel represent the number of cases in each data

596 release. A representation of these signals across the Covid-19hgi releases is available as Figure S50.

597

598

599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614

Tables

Table 1. Sample sizes for each analysis, as of 06.18.21

Phenotype	Controls	Ancestry	Sex-stratified	Cases	Controls	Female Cases	Female Controls
Susceptibility (06.18.21 release)	Test negative OR not tested (Population)	ALL	yes	18,481	468,839	9,757	254,472
		EUR	yes	16,551	442,699	8,767	240,532
		AFR		557	7,087	316	4,043
		SAS		810	8,607	351	3,980
		OTHERS		563	10,446	323	5,917
		nEUR		1,930	26,140	990	13,940
	Test negative (Tested)	ALL	yes	18,481	86,435	9,757	46,737
		EUR	yes	16,551	81,826	8,767	44,248
		AFR		557	1,281	316	759
		SAS		810	1,516	351	695
		OTHERS		563	1,812	323	1,035
		nEUR		1,930	4,609	990	2,489
Hospitalization (06.18.21 release)	Not hospitalized (Population)	ALL	yes	3,260	484,060	1,343	262,886
		EUR	yes	2,884	456,366	1,181	248,118
		nEUR		376	27,694	162	14,768
	Tested, not hospitalized (Tested)	ALL	yes	3,260	101,656	1,343	55,151
		EUR	yes	2,884	95,493	1,181	51,834
		nEUR		376	6,163	162	3,317
	Test positive, not hospitalized (Positive)	ALL	yes	3,260	15,221	1,343	8,414
		EUR	yes	2,884	13,667	1,181	7,586

		nEUR		376	1,554	162	828
Severe Covid-19 (05.09.21 release)	Not severe (Population)	ALL	yes	1,244	486,076	439	263,790
		EUR	yes	1,120	458,130	387	248,912
	Tested, not severe (Tested)	ALL	yes	1,244	84,742	439	45,811
		EUR	yes	1,120	79,439	387	42,973
	Test positive, not severe (Positive)	ALL	yes	1,244	16,413	439	8,866
		EUR	yes	1,120	14,695	387	7,976
Death (05.09.21 release)	Survivor (Population)	ALL		1,104	486,216	399	263,830
		EUR		1,001	458,249	356	248,943
	Tested, survivor (Tested)	ALL		1,104	84,882	399	45,851
		EUR		1,001	79,558	356	43,004
	Test positive, survivor (Positive)	ALL		1,104	16,553	399	8,906
		EUR		1,001	14,814	356	8,007

ALL: All ancestries; EUR: European ancestry; AFR: African ancestry; SAS: South Asian ancestry; OTHERS: Ancestry different from EUR, AFR and SAS; nEUR: non-EUR ancestry.

615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631

Table 2. Composition of the consecutive UK Biobank Covid-19 data releases

Release Date	Cases (tested positive)	Controls	% Tested Positive Females	Age Cases ^a
05.07.20 ^b	1,029	486,291	45.29	57.02 (9.12)
05.25.20 ^b	1,270	486,050	46.93	56.57 (9.25)
06.05.20	1,412	485,908	47.31	56.45 (9.23)
06.18.20	1,485	485,835	47.21	56.47 (9.19)
07.14.20	1,670	485,650	46.59	56.89 (9.14)
08.04.20	1,723	485,597	46.66	56.77 (9.11)
09.08.20	1,821	485,499	46.73	56.66 (9.10)
10.16.20	3,050	484,270	48.69	55.19 (9.09)
11.03.20	4,372	482,948	49.38	54.79 (8.95)
11.25.20	5,868	481,452	49.52	54.56 (8.88)
12.04.20	7,435	479,885	50.46	54.36 (8.80)
01.04.21	8,722	478,598	50.50	54.28 (8.79)

01.22.21	13,401	473,919	52.27	53.85 (8.66)
02.02.21	14,802	472,518	52.44	53.81 (8.64)
02.24.21	15,738	471,582	52.47	53.77 (8.63)
04.04.21	16,586	470,734	52.68	53.70 (8.62)
05.09.21	17,657	469,663	52.70	53.64 (8.62)
06.18.21	18,481	468,839	52.79	53.57 (8.60)

632

633 ^a Mean baseline Age (standard deviation), at recruitment

634 ^b For the first 2 releases, the numbers reflect all ancestries, but only cases and controls of European ancestry were
635 considered for analyses

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653 **Table 3. Lead variants associated with Covid-19 phenotypes**

654

Analysis:Ancestry:Controls(:Sex) ^a	CHR:POS:NEA:EA	rsid	EAF	OR	±95CI	P	Locus
Susceptibility:ALL:Population:F	2:192774154:G:A	rs147509469	0.037	1.2589	[1.16; 1.37]	2.64E-08	CAVIN2;TMEFF2
Susceptibility:ALL:Population	3:45835417:G:A	rs73062389	0.058	1.2070	[1.15; 1.27]	4.26E-15	SLC6A20
Hospitalization:ALL:Population	3:45850783:T:A	rs72893671	0.081	1.4043	[1.28; 1.54]	5.12E-13	SLC6A20;LZTFL1
Severe:ALL:Population	3:45862952:T:C	rs71325088	0.073	1.6206	[1.38; 1.90]	2.25E-09	SLC6A20;LZTFL1
Susceptibility:ALL:Population	9:136145425:C:A	rs9411378	0.219	1.1013	[1.07; 1.13]	3.30E-12	ABO
Susceptibility:nEUR:Population	10:78250184:T:C	rs114026383	0.016	2.3943	[1.79; 3.20]	4.10E-09	LRMDA
Death:ALL:Population	19:45411941:T:C	rs429358	0.154	1.3983	[1.24; 1.57]	3.06E-08	APOE

655

656 ^a Indicate the ancestry by label, the control set, and, when it is the case, the corresponding sex-stratified analyses (F: Females,
657 M: Males)

658 CHR: Chromosome; POS: Position (hg19 genome build); NEA: Non Effect Allele; EA: Effect Allele; EAF: Effect Allele Frequency;

659 OR: Odd-ratio; ±95CI: 95% confidence interval [lower bound; upper bound]; P: P-value (from the last data release, analyzed on

660 06.18.21 for susceptibility and hospitalization, and 05.09.21 for severe and death phenotypes)

661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691

Table 4. Signals with a positive significance trajectory in UKB, sorted by their P-value in their equivalent Covid-19hgi meta-analyses (top 10)

Phenotype	CHR:POS:NEA:EA	UKB					COVID-19hgi (without UKB)				Locus
		rsid	MAF	BETA	SE	P	ANALYSIS	BETA	SE	P	
Hospitalization	3:45848760:G:C	rs17712877	0.07	0.340	0.050	9.28E-12	B2	0.387	0.023	8.01E-64	SLC6A20;LZTFL1
Susceptibility	9:136149229:T:C	rs505922	0.32	0.071	0.012	1.04E-09	C2	0.074	0.005	2.44E-60	ABO
Susceptibility	3:45835417:G:A	rs73062389	0.06	0.188	0.024	4.26E-15	C2	0.158	0.010	1.08E-54	SLC6A20
Severe	3:45889921:A:T	rs35081325	0.07	0.468	0.081	6.65E-09	A2	0.633	0.044	5.29E-46	LZTFL1
Hospitalization	19:4723670:C:A	rs2277732	0.30	0.113	0.028	4.64E-05	B2	0.131	0.014	4.26E-22	DPP9
Hospitalization	9:136149500:T:C	rs529565	0.32	0.107	0.027	7.12E-05	B2	0.106	0.012	7.10E-18	ABO
Susceptibility	3:101503765:G:A	rs4342086	0.35	-0.046	0.012	6.62E-05	C2	-0.039	0.005	8.22E-17	NXPE3
Hospitalization	4:25464527:T:C	rs12507905	0.13	0.178	0.037	1.69E-06	B2	0.053	0.016	1.04E-3	ANAPC4;LOC101929161
Hospitalization	17:1441448:A:G	rs6502772	0.18	0.130	0.033	9.56E-05	B2	0.056	0.018	1.42E-3	PITPNA
Hospitalization	1:77954397:G:C	rs12034334	0.18	0.133	0.033	6.71E-05	B2	0.051	0.016	1.51E-3	AK5

692
693
694
695
696
697
698

^a Indicate the phenotype, the ancestry, the control set, and, when it is the case, the corresponding sex-stratified analyses (F: Females, M: Males)
CHR: Chromosome; POS: Position (hg19 genome build); NEA: Non Effect Allele; EA: Effect Allele; MAF: Minor Allele Frequency; SE: Standard Error; P: P-value (from the last data release, analyzed on 06.18.21 for susceptibility and hospitalization, and 05.09.21 for severe and death phenotypes)

